E. Kneepkens

Therapeutic drug monitoring to optimize biological treatment: opportunities and challenges

E. Kneepkens, 2016 .

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

M. Hart, C. Plasencia, A. Balsa, 2017, Scandinavian journal of rheumatology.

SAT0397 Comparison of Long-Term Drug Survival Outcome with Etanercept Treatment and Adalimumab Treatment of Ankylosing Spondylitis

M. Nurmohamed, G. Wolbink, I. E. van der Horst-Bruinsma, 2016 .

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab

M. Nurmohamed, G. Wolbink, I. E. van der Horst-Bruinsma, 2018, Scandinavian journal of rheumatology.

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

M. Boers, M. Nurmohamed, T. Rispens, 2022, Scandinavian journal of rheumatology.

Search for a concentration–effect curve of adalimumab in ankylosing spondylitis patients

M. Nurmohamed, T. Rispens, G. Wolbink, 2016, Scandinavian journal of rheumatology.

THU0208 Efficacy of Switching Tumor Necrosis Factor α Inhibitor to a Second Tumor Necrosis Factor α Inhibitor and the Influence of Drug Levels and Anti-Drug Antibodies in Patients with Ankylosing Spondylitis and Psoriatic Arthritis

M. Nurmohamed, T. Rispens, G. Wolbink, 2015 .

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

G. Wolbink, M. Nurmohamed, T. Rispens, 2013, Annals of the rheumatic diseases.